About
The Journal "Obstetrics and Gynecology"Journal HistoryAims and ScopePolicies on Conflict of Interest, Human and Animal Rights, and Informed ConsentEditorial ProcessData sharing statementAdvertising PolicyThe Process for Handling Cases Requiring Corrections, Retractions, and Editorial Expressions of ConcernEditorial BoardEditorial CounsilInformation for ProfessionalsNewsContacts
ArchiveEthical StandardsSubscription
For authors
InstructionsInformed consent policyContract offerEASE GuidelinesICJME CriteriaWAME Recommendations on ChatGPT and Chatbots in Relation to Scholarly Publications
Reviewing
Procedure for reviewingReviewers 2023-2024
About
The Journal "Obstetrics and Gynecology"Journal HistoryAims and ScopePolicies on Conflict of Interest, Human and Animal Rights, and Informed ConsentEditorial ProcessData sharing statementAdvertising PolicyThe Process for Handling Cases Requiring Corrections, Retractions, and Editorial Expressions of ConcernEditorial BoardEditorial CounsilInformation for ProfessionalsNewsContacts
ArchiveEthical StandardsSubscription
For authors
InstructionsInformed consent policyContract offerEASE GuidelinesICJME CriteriaWAME Recommendations on ChatGPT and Chatbots in Relation to Scholarly Publications
Reviewing
Procedure for reviewingReviewers 2023-2024
Logout
Obstetrics and Gynegology2022№9
Predictors of development and progression...

Predictors of development and progression of cervical dysplastic processes

DOI
https://dx.doi.org/10.18565/aig.2022.9.19-24

Levakov S.A., Mushkyurova D.R., Sheshukova N.A., Obukhova E.A.

I.M. Sechenov First Moscow State Medical University, Ministry of Health of the Russian Federation (Sechenov University), Moscow, Russia
Cervical cancer (CC) ranks fourth in the structure of morbidity and mortality from cancers in women. Early detection of CC and assessment of malignancy prognoses are of critical importance, because women who have early-stage invasive carcinoma have significantly higher chances of being cured, which is in turn cost effective. Publications in the PubMed and Cochrane databases; recommendations of international and Russian professional communities, clinical studies published in the public domain to search for modern markers for the progression of cervical precancerous processes have been analyzed. The review presents markers for the progression of cervical precancerous processes and describes the main mechanisms of the pathogenic effect of human papillomavirus (HPV) on epithelial cells. Along with well-known markers, such as p16, Ki-67, proteomics that is a valuable tool for studying the mechanisms involved in the interaction of viral infection and protein dysfunction leading to cervical carcinogenesis is being actively investigated. Metabolomics is widely used to study cancer metabolism. Metabolites, the end products of various biological processes, hold promise as accurate biomarkers that reflect past biological events, such as genetic mutations and environmental changes. Altered metabolites will help to better understand metabolic dysregulation during tumor initiation and progression.
Conclusion: An analysis of the data available in the literature has shown that markers for dysplasia progression enhance the possibilities of timely diagnosis and therapy.

Keywords

cervix
cervical intraepithelial neoplasia (CIN)
immunohistochemistry
Ki-67
p16/INK4a
human papillomavirus (HPV)
LSIL
HSIL
Full text (in Russian)

References

  1. Sung H., Ferlay J., Siegel R.L., Laversanne M., Soerjomataram I., Jemal A., Bray F. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 2021; 71(3): 209-49. https://dx.doi.org/10.3322/caac.21660.
  2. Ашрафян Л.А., Киселев В.И., Кузнецов И.Н., Серова О.Ф., Узденова З.Х., Герфанова Е.В. Рак шейки матки: проблемы профилактики и скрининга в Российской Федерации. Доктор.Ру. 2019; 11: 50-4. [Ashrafyan L.A., Kiselev V.I., Kuznetsov I.N., Serova O.F., Uzdenova Z.Kh., Gerfanova E.V. Cervical cancer: issues with prevention and Screening in the Russian Federation. Doctor.Ru. 2019; 11: 50-4. (in Russian)]. https://dx.doi.org/10.31550/1727-2378-2019-166-11-50-54.
  3. Pappa K.I., Kontostathi G., Lygirou V., Zoidakis J., Anagnou N.P. Novel structural approaches concerning HPV proteins: Insight into targeted therapies for cervical cancer (Review). Oncol. Rep. 2018; 39(4): 1547-54.https://dx.doi.org/10.3892/or.2018.6257.
  4. Bogani G., Leone Roberti Maggiore U., Signorelli M., Martinelli F., Ditto A., Sabatucci I. et al. The role of human papillomavirus vaccines in cervical cancer: Prevention and treatment. Crit. Rev. Oncol. Hematol. 2018; 122: 92-7.https://dx.doi.org/10.1016/j.critrevonc.2017.12.017.
  5. IARC. Working Group on the evaluation of carcinogenic risks to humans. Geneva: WHO; 1995.
  6. Cubie H.A., Cuschieri K.S., Tong C.Y.W. Papillomaviruses and polyomaviruses. In: Greenwood D., Barer M., Slack R., Irving W., eds. Medical microbiology. 18th ed. London: Churchill Livingstone Elsevier; 2012.
  7. Bergeron C., Ronco G., Reuschenbach M., Wentzensen N., Arbyn M., Stoler M. et al. The clinical impact of using p16INK4a immunochemistry in cervical histopathology and cytology: an update of recent developments. Int. J. Cancer. 2015; 136(12): 2741-51. https://dx.doi.org/10.1002/ijc.28900.
  8. Narisawa-Saito M., Kiyono T. Basic mechanisms of high-risk human papillomavirus-induced carcinogenesis: roles of E6 and E7 proteins. Cancer Sci. 2007; 98(10): 1505-11. https://dx.doi.org/10.1111/j.1349-7006.2007.00546.x.
  9. Münger K., Basile J.R., Duensing S., Eichten A., Gonzalez S.L., Grace M., Zacny V.L. Biological activities and molecular targets of the human papillomavirus E7 oncoprotein. Oncogene. 2001; 20(54): 7888-98. https://dx.doi.org/10.1038/sj.onc.1204860.
  10. Howley P.M. Warts, cancer and ubiquitylation: lessons from the papillomaviruses. Trans. Am. Clin. Climatol. Assoc. 2006; 117: 113-26; discussion 126-7.
  11. Oyervides-Muñoz M.A., Pérez-Maya A.A., Rodríguez-Gutiérrez H.F., Gómez-Macias G.S., Fajardo-Ramírez O.R., Treviño V. et al. Understanding the HPV integration and its progression to cervical cancer. Infect. Genet. Evol. 2018; 61: 134-44. https://dx.doi.org/10.1016/j.meegid.2018.03.003.
  12. Lau L., Gray E.E., Brunette R.L., Stetson D.B. DNA tumor virus oncogenes antagonize the cGAS-STING DNA-sensing pathway. Science. 2015;350(6260): 568-71. https://dx.doi.org/10.1126/science.aab3291.
  13. Groves I.J., Coleman N. Pathogenesis of human papillomavirus-associated mucosal disease. J Pathol. 2015; 235(4): 527-38. https://dx.doi.org/10.1002/path.4496.
  14. Wright A.A., Howitt B.E., Myers A.P., Dahlberg S.E., Palescandolo E., Van Hummelen P. et al. Oncogenic mutations in cervical cancer: genomic differences between adenocarcinomas and squamous cell carcinomas of the cervix. Cancer. 2013; 119(21): 3776-83. https://dx.doi.org/10.1002/cncr.28288.
  15. Bergeron C., Ikenberg H., Sideri M., Denton K., Bogers J., Schmidt D. et al.Prospective evaluation of p16/Ki‑67 dual-stained cytology for managing women with abnormal Papanicolaou cytology: PALMS study results. Cancer Cytopathol. 2015; 123(6): 373-81. https://dx.doi.org/10.1002/cncy.21542.
  16. Branca M., Ciotti M., Giorgi C., Santini D., Di Bonito L., Costa S. et al. Predicting high-risk human papillomavirus infection, progression of cervical intraepithelial neoplasia, and prognosis of cervical cancer with a panel of 13 biomarkers tested in multivariate modeling. Int. J. Gynecol. Pathol. 2008; 27(2): 265-73.https://dx.doi.org/10.1097/PGP.0b013e318159cbc0.
  17. Трухачёва Н.В. Медицинская статистика: учебное пособие. Ростов-на-Дону: Феникс; 2017. [Trukhacheva N.V. Medical statistics: textbook. Rostov-on-Don: Phoenix; 2017. (in Russian)].
  18. Межевитинова Е.А., Абакарова П.Р., Хлебкова Ю.С. Предраковые поражения шейки матки. Тактика ведения. Медицинский совет. 2016; 12: 112-8. [Mezhevitinova E.A., Abakarova P.R., Khlebkova Y.S. Precancerous cervical lesions. Treatment approach. Medical Council. 2016; (12): 112-8. (in Russian)]. https://dx.doi.org/10.21518/2079-701X-2016-12-112-118.
  19. Ikenberg H., Bergeron C., Schmidt D., Griesser H., Alameda F., Angeloni C. et al.; PALMS Study Group. Screening for cervical cancer precursors with p16/Ki-67 dual-stained cytology: results of the PALMS study. J. Natl. Cancer Inst. 2013; 105(20): 1550-7. https://dx.doi.org/10.1093/jnci/djt235.
  20. Prendiville W., Sankaranarayanan R. Colposcopy and treatment of cervical precancer. Lyon IARC; 2017. (IARC Technical Report, No. 45.) Annex 1. Transformation zone types. Available at: https://www.ncbi.nlm.nih.gov/books/NBK568386/
  21. Nam E.J., Kim J.W., Kim S.W., Kim Y.T., Kim J.H., Yoon B.S. et al. The expressions of the Rb pathway in cervical intraepithelial neoplasia; predictive and prognostic significance. Gynecol. Oncol. 2007; 104(1): 207-11.https://dx.doi.org/10.1016/j.ygyno.2006.07.043.
  22. Feng W., Xiao J., Zhang Z., Rosen D.G., Brown R.E., Liu J., Duan X. Senescence and apoptosis in carcinogenesis of cervical squamous carcinoma. Mod. Pathol. 2007; 20(9): 961-6. https://dx.doi.org/10.1038/modpathol.3800927.
  23. Valenti G., Vitale S.G., Tropea A., Biondi A., Laganà A.S. Tumor markers of uterine cervical cancer: a new scenario to guide surgical practice? Updates Surg. 2017; 69(4): 441-9. https://dx.doi.org/10.1007/s13304-017-0491-3.
  24. Zhu X., Jin L., Zou S., Shen Q., Jiang W., Lin W., Zhu X. Immunohistochemical expression of RAGE and its ligand (S100A9) in cervical lesions. Cell Biochem. Biophys. 2013; 66(3): 843-50. https://dx.doi.org/10.1007/s12013-013-9515-x.
  25. Yang L., Bai H.-S., Deng Y., Fan L. High MALAT1 expression predicts a poor prognosis of cervical cancer and promotes cancer cell growth and invasion. Eur. Rev. Med. Pharmacol. Sci. 2015; 19(17): 3187-93.
  26. Liang T., Wang Y., Jiao Y., Cong S., Jiang X., Dong L. et al. LncRNA MALAT1 accelerates cervical carcinoma proliferation by suppressing miR-124 expression in cervical tumor cells. J. Oncol. 2021; 2021: 8836078.https://dx.doi.org/10.1155/2021/8836078.
  27. Леваков С.А., Шешукова Н.А., Обухова Е.А., Антипова Н.В., Павлюков М.С., Шахпаронов М.И. Уровень экспрессии параоксоназ при диспластических процессах шейки матки. Акушерство и гинекология. 2020; 2: 149-53. [Levakov S.A., Sheshukova N.A., Obukhova E.A., Antipova N.V., Pavlyukov M.S., Shakhparonov M.I. The expression level of paraoxonases in cervical dysplastic processes. Obstetrics and Gynecology. 2020; 2: 149-53.(in Russian)]. https://dx.doi.org/10.18565/aig.2020.2.149-153.
  28. El-Mansi M.T., Williams A.R. Evaluation of PTEN expression in cervical adenocarcinoma by tissue microarray. Int. J. Gynecol. Cancer. 2006; 16(3): 1254-60. https://dx.doi.org/10.1111/j.1525-1438.2006.00569.x.
  29. Wang P.H., Ko J.L., Tsai H.T., Yang S.F., Han C.P., Lin L.Y., Chen G.D. et al. Clinical significance of matrix metalloproteinase-2 in cancer of uterine cervix: a semiquantitative study of immunoreactivities using tissue array. Gynecol. Oncol. 2008; 108(3): 533-42. https://dx.doi.org/10.1016/j.ygyno.2007.11.018.
  30. Cao X.Q., Lu H.S., Zhang L., Chen L.L., Gan M.F. MEKK3 and survivin expression in cervical cancer: association with clinicopathological factors and prognosis. Asian Pac. J. Cancer Prev. 2014; 15(13): 5271-6.https://dx.doi.org/10.7314/apjcp.2014.15.13.5271.
  31. Blancas S., Medina-Berlanga R., Ortíz-García L., Loredo-Ramírez A., Santos L. Protein expression analysis in uterine cervical cancer for potential targets in treatment. Pathol. Oncol. Res. 2019; 25(2): 493-501.https://dx.doi.org/10.1007/s12253-018-0401-0.
  32. Nicholson J.K., Lindon J.C. Systems biology: metabonomics. Nature. 2008; 455(7216): 1054-6. https://dx.doi.org/10.1038/4551054a.
  33. Zielinski D., Jamshidi N., Corbett A.J., Bordbar A., Thomas A., Palsson B.O. Systems biology analysis of drivers underlying hallmarks of cancer cell metabolism. Sci. Rep. 2017; 7: 41241. https://dx.doi.org/10.1186/1752-0509-6-9.
  34. Ye N., Liu C., Shi P. Metabolomics analysis of cervical cancer, cervical intraepithelial neoplasia and chronic cervicitis by 1H NMR spectroscopy. Eur. J. Gynaecol. Oncol. 2015; 36(2): 174-80.
  35. Yin M.Z., Tan S., Li X., Hou Y., Cao G., Li K. et al. Identification of phosphatidylcholine and lysophosphatidylcholine as novel biomarkers for cervical cancers in a prospective cohort study. Tumour Biol. 2016; 37(4): 5485-92. https://dx.doi.org/10.1007/s13277-015-4164-x.
  36. Hasim A., Aili A., Maimaiti A., Mamtimin B., Abudula A., Upur H. Plasma-free amino acid profiling of cervical cancer and cervical intraepithelial neoplasia patients and its application for early detection. Mol. Biol. Rep. 2013; 40(10): 5853-9. https://dx.doi.org/ 10.1007/s11033-013-2691-3.
  37. Ramchander N.C., Crosbie E.J. The role of the vaginal microbiome and gynaecological cancer: exercise caution when considering causation. BJOG. 2018; 125(3): 316. https://dx.doi.org/10.1111/1471-0528.14704.
  38. Piyathilake C.J., Ollberding N.J., Kumar R., Macaluso M., Alvarez R.D., Morrow C.D. Cervical microbiota associated with higher grade cervical intraepithelial neoplasia in women infected with high-risk human papillomaviruses. Cancer Prev. Res. (Phila). 2016; 9(5): 357-66.https://dx.doi.org/10.1158/1940-6207.CAPR-15-0350.
  39. Adebamowo S.N., Ma B., Zella D., Famooto A., Ravel J.; ACCME Research Group. Mycoplasma hominis and mycoplasma genitalium in the vaginal microbiota and persistent high-risk human papillomavirus infection. Front. Public Health. 2017; 5: 140. https://dx.doi.org/10.3389/fpubh.2017.00140.
  40. Yang X., Da M., Zhang W., Qi Q., Zhang C., Han S. Role of Lactobacillus in cervical cancer. Cancer Manag. Res. 2018; 10: 1219-29. https://dx.doi.org/10.2147/CMAR.S165228.

Received 26.05.2022

Accepted 25.08.2022

About the Authors

Sergey A. Levakov, Dr. Med. Sci., Professor, Head of the Department of Obstetrics and Gynecology of N.V. Sklifosovsky ICM, I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia (Sechenov University), levakoff@yandex.ru , 119991, Russia, Moscow, Trubetskaya str., 8-2.
Diana R. Mushkyurova, postgraduate student of the Department of Obstetrics and Gynecology of the N.V. Sklifosovsky ICM, I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia (Sechenov University), dr.ramazanovna@gmail.com, 119991, Russia, Moscow, Trubetskaya str., 8-2.
Natalia A. Sheshukova, Dr. Med. Sci., Professor at the Department of Obstetrics and Gynecology of the N.V. Sklifosovsky ICM, I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia (Sechenov University), dr.sheshukova@mail.ru, 119991, Russia, Moscow, Trubetskaya str., 8-2.
Elizaveta A. Obukhova, Teaching Assistant at the Department of Obstetrics and Gynecology of N.V. Sklifosovsky ICM, I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia (Sechenov University), liza_obukhova@mail.ru, 119991, Russia, Moscow, Trubetskaya str., 8-2.
Corresponding author: Diana R. Mushkyurova, r.ramazanovna@gmail.com

Authors' contributions: Levakov S.A. – an investigation supervisor; Mushkyurova D.R. – analysis and collection of literature data; Sheshukova N.A. – editing the text; Obukhova E.A. – idea of the investigation.
Conflicts of interest: The authors declare that there is no need to disclose conflicts of interest related to this publication.
Funding: The authors declare that there is no need to disclose financial support related to this publication.
For citation: Levakov S.A., Mushkyurova D.R., Sheshukova N.A., Obukhova E.A.
Predictors of development and progression of cervical dysplastic processes.
Akusherstvo i Ginekologiya/Obstetrics and Gynecology. 2022; 9: 19-24 (in Russian)
https://dx.doi.org/10.18565/aig.2022.9.19-24

Similar Articles

№11 / 2023
Andreev A.O., Bayramova G.R., Ilyasova N.A., Asaturova A.V., Trofimov D.Yu.
Retrospective analysis of human papillomavirus prevalence in women with cervical pathology
№10 / 2021
Boris D.A., Tyutyunnik V.L., Kan N.E., Shchegolev A.I., Sinitsyna V.A., Sadekova A.A., Krasnyi A.M.
Features of changes in the monocyte-macrophage cells in the placenta during preeclampsia
№8 / 2021
Remneva O.B., Kolyado O.V., Pesotskaya A.V., Starodubtsev E.G., Gumenyuk I.S.
Pathomorphological features of placenta in patients with different clinical phenotypes of spontaneous preterm births
№4 / 2024
Lipatov I.S., Tezikov Yu.V., Tyutyunnik V.L., Kan N.E., Martynyuk D.A., Belousov I.S.
Rationale for preoperative treatment of advanced-stage endometrial ovarian cysts in infertile women
№4 / 2024
Klinyshkova T.V., Buyan M.S., Samosudova I.B.
Recurrence of cervical intraepithelial neoplasia: modern view on the problem
By continuing to use our site, you consent to the processing of cookies that ensure the proper functioning of the site.